News | September 20, 2024
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
Stable profits, low leverage to keep credit profiles comfortable
Stable profits, low leverage to keep credit profiles comfortable
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Subscribe To Our Newsletter & Stay Updated
